Találati lista | Tudóstér

001-es BibID:	BIBFORM034576
Első szerző:	Simon Ágnes (laboratóriumi szakorvos)
Cím:	Expression of coagulation factor XIII subunit A in acute promyelocytic leukemia / Ágnes Simon, Zsuzsa Bagoly, Zsuzsanna Hevessy, László Csáthy, Éva Katona, György Vereb, Anikó Ujfalusi, László Szerafin, László Muszbek, János Kappelmayer
Dátum:	2012
ISSN:	1552-4949
Megjegyzések:	Leukemic cells often express markers which are not characteristic of their particular cell lineage. In this study we identified the "A" subunit of coagulation factor XIII (FXIII-A) in leukemic promyelocytes in de novo AML M3 cases. The cytoplasmic presence of factor XIII-A has previously been shown only in platelets/megakaryocytes and monocytes/macrophages. Furthermore, more recently we described the presence of FXIII-A in leukemic lymphoblasts. We studied 14 patients with this rare type of acute leukemia in a period of 4 years and investigated their bone marrow samples by 3-color flow cytometry upon diagnosis, mainly focusing on FXIII-A expression of leukemic cells. We detected FXIII-A also by ELISA, Western-blot and confocal laser scanning microscopy. This was a homogenous group of AML M3 patients with translocation t(15;17)(q22;q21) detected by fluorescence in situ hybridization (FISH). In 10 out of 14 samples, FXIII-A was detectable by flow cytometry and was coexpressed with markers characteristic for leukemic promyleocytes (CD45dim/CD13+/CD33+/CD117+/cyMPO+ and HLA-DR-/CD34-/CD14-/CD15-). Staining for the markers GPIIb and GPIX were negative, and FXIII-A was identified in the cytoplasm of the cells by confocal microscopy in a relatively high quantity, as measured by ELISA. By Western blot analysis we could identify FXIII-A in the native 82 kD form and in cleaved forms corresponding to cleavage products observed when purified FXIII-A was treated by human neutrophil elastase. Since normal promyelocytes were FXIII-A negative, this novel expression site of FXIII-A in AML M3 can be considered as a leukemia associated immunophenotype and may have pathophysiological significance.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény Molekuláris Medicina
Megjelenés:	Cytometry. Part B. Clinical Cytometry. - 82B : 4 (2012), p. 209-216. -
További szerzők:	Bagoly Zsuzsa (1978-) (orvos) Hevessy Zsuzsanna (1966-) (laboratóriumi szakorvos) Csáthy László (1979-) (laboratóriumi szakorvos) Katona Éva (1961-) (klinikai biokémikus) Vereb György (1965-) (biofizikus, orvos) Ujfalusi Anikó (1968-) (gyermekorvos, laboratóriumi szakorvos) Szerafin László (1958-) (belgyógyászat, haematológia, klinikai onkológia szakorvos) Muszbek László (1942-) (haematológus, kutató orvos) Kappelmayer János (1960-) (laboratóriumi szakorvos)
Pályázati támogatás:	TÁMOP-4.2.1/B-09/1/KONV-2010-0007 TÁMOP Celluláris hematológia - immunológia TÁMOP-4.2.1/B-09/1/KONV-2010-0007 TÁMOP A véralvadás XIII-as faktorának (FXIII) struktúrája, funkciója, előfordulása egyéb testnedvekben és kapcsolata trombotikus megbetegedésekkel
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM118894
035-os BibID:	(cikkazonosító)1329236
Első szerző:	Tóth Eszter Lilla
Cím:	Case report : Complex evaluation of coagulation, fibrinolysis and inflammatory cytokines in a SARS-CoV-2 infected pregnant woman with fetal loss / Tóth Eszter Lilla, Orbán-Kálmándi Rita, Bagoly Zsuzsa, Lóczi Linda, Deli Tamás, Török Olga, Molnár Sarolta, Baráth Sándor, Singh Parvind, Hevessy Zsuzsanna, Katona Éva, Fagyas Miklós, Szabó Attila Ádám, Molnár Szabolcs, Krasznai Zoárd Tibor
Dátum:	2024
ISSN:	1664-3224
Megjegyzések:	Background: SARS-CoV-2 infection during pregnancy increases the risk of severe obstetrical complications. Detailed evaluation of COVID-19-associated coagulopathy in a pregnancy with stillbirth hasn't been described so far. Besides knowledge gaps in the pathomechanism leading to stillbirth in COVID-19 pregnancies, currently, no prognostic biomarker is available to identify pregnant patients who are at imminent risk of COVID-19-associated maternal and fetal complications, requiring immediate medical attention. Case: Here we report the case of a 28-year-old SARS-CoV-2 infected pregnant patient, admitted to our hospital at 28 weeks of gestation with intrauterine fetal loss. The presence of SARS-CoV-2 placentitis was confirmed by immunohistological evaluation of the placenta. She had only mild upper respiratory symptoms and her vital signs were within reference throughout labor and postpartum. The stillborn infant was delivered per vias naturales. Fibrinogen concentrate was administered before and after labor due to markedly decreased fibrinogen levels (1.49 g/l) at admission and excessive bleeding during and after delivery. Although coagulation screening tests were not alarming at admission, the balance of hemostasis was strikingly distorted in the patient. As compared to healthy age- and gestational age-matched pregnant controls, increased D-dimer, low FVIII activity, low FXIII level, marked hypocoagulability as demonstrated by the thrombin generation assay, together with shortened clot lysis and decreased levels of fibrinolytic proteins were observed. These alterations most likely have contributed to the increased bleeding observed during labor and in the early postpartum period. Interestingly, at the same time, only moderately altered inflammatory cytokine levels were found at admission. Serum ACE2 activity did not differ in the patient from that of age- and gestational age-matched healthy controls, suggesting that despite previous speculations in the literature, ACE2 may not be used as a potential biomarker for the prediction of COVID-19 placentitis and threatening fetal loss in SARS-CoV-2-infected pregnancies. Conclusions: Although based on this case report no prognostic biomarker could be identified for use in pregnant patients with imminent risk of fetal loss associated with COVID-19 placentitis, the above-described hemostasis alterations warrant awareness of postpartum hemorrhagic complications and could be helpful to identify patients requiring intensified medical attention.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok esettanulmány folyóiratcikk COVID 19 fetal death hemostasis placenta case report stillbirth
Megjelenés:	Frontiers in Immunology. - 15 (2024), p. 1-10. -
További szerzők:	Orbán-Kálmándi Rita Angéla (1993-) (klinikai laboratóriumi kutató) Bagoly Zsuzsa (1978-) (orvos) Lóczi Linda Deli Tamás (1979-) (szülész-nőgyógyász, endokrinológus szakorvos) Török Olga (1956-) (szülész-nőgyógyász, humángenetikus) Deliné Molnár Sarolta (1990-) (patológus) Baráth Sándor (1977-) (biológus) Singh, Parvind (1995-) (PhD hallgató) Hevessy Zsuzsanna (1966-) (laboratóriumi szakorvos) Katona Éva (1961-) (klinikai biokémikus) Fagyas Miklós (1984-) (orvos) Szabó Attila Ádám (1996-) (orvos) Molnár Szabolcs (1987-) (szülész-nőgyógyász szakorvos) Krasznai Zoárd Tibor (1973-) (szülész-nőgyógyász, gyermeknőgyógyász)
Pályázati támogatás:	NKFI FK128582 Egyéb TKP 2021 EGA-19 Egyéb ÚNKP 22-3-II-DE-167 Egyéb ÚNKP-23-5-DE-482 Egyéb POST-COVID2021-33 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: